In a cohort of 595 breast cancer patients, Caudle et al. showed that patients with HR+/HER2− and HR+/HER2+ subsets had excellent LRR-free survival regardless of tumor response to neoadjuvant chemotherapy. The gene discussed is ERBB2; the disease is neoplasm.